Moderna explores outside financing for vaccine trials, shares dip

June 13, 2025 01:35 AM AEST | By Investing

Google News:

Moderna explores outside financing for vaccine trials, shares dip — Image source: Kalkine Media

Recent News

AMD Advancing AI event: Here’s how Wall Street analysts reacted

PotlatchDeltic’s Carbon Storage

Charles Schwab stock falls after monthly report shows drop in new acco...

From Vietnam: Cascale, Worldly Forge New Partnership Momentum

Investing.com -- Moderna Inc (BMV:MRNA) (NASDAQ:MRNA) shares fell 2.2% Thursday as the company confirmed it is seeking outside investment to support its late-stage vaccine programs. The move underscores the biotech firm’s effort to align capital efficiency with strategic advancement across its product pipeline amid slowing COVID-19 revenue.

“We are very actively talking to potential partners right now,” CEO Stéphane Bancel said Wednesday at the Goldman Sachs (NYSE:GS) Annual Global Healthcare Conference. He added that the discussions involved both pharmaceutical companies and financial partners, enabling the company to progress stalled late-stage candidates while controlling costs.

A key focus for potential funding includes its latent virus vaccine programs, such as those targeting Epstein-Barr virus (EBV), herpes simplex virus (HSV), and varicella-zoster virus (VZV). “We are working actively with [a] pharma company on the one hand and [a] financial partner on the other hand because we want those products to get to phase three,” Bancel said.

Moderna has paused internal spending for those programs, opting instead to secure external capital and avoid further capital expenditure. “We could launch EBV without adding $1 of CapEx. We could launch HSV without adding $1 of CapEx,” Bancel said, noting that Moderna’s existing facilities have sufficient capacity to support production without the need for additional investment.

The company’s earlier collaboration with Blackstone (NYSE:BX) on financing a flu vaccine program stands as a precedent for these new deal structures. “We would rather wait a few months to get the best partnership than being in a hurry and destroy value for shareholders by being in a hurry,” Bancel noted.

While the company has over $8.5 billion in cash on hand, Bancel indicated this financing effort is about maximizing efficiency, not bridging funding gaps. “We want to figure out who is the best partner in terms of capabilities and in terms of value,” he said, reiterating that securing the right structure is more important than speed.

The funding push comes as Moderna aims to return to profitability by 2028 while ramping its oncology and respiratory portfolios. Shares finished the day down 2.2%, reflecting cautious sentiment amid uncertainty around vaccine uptake, trial timelines, and partnering outcomes.

This article first appeared in Investing.com

Disclaimer

The content, including but not limited to any articles, news, quotes, information, data, text, reports, ratings, opinions, images, photos, graphics, graphs, charts, animations and video (Content) is a service of Kalkine Media Pty Ltd (“Kalkine Media, we or us”), ACN 629 651 672 and is available for personal and non-commercial use only. The principal purpose of the Content is to educate and inform. The Content does not contain or imply any recommendation or opinion intended to influence your financial decisions and must not be relied upon by you as such. Some of the Content on this website may be sponsored/non-sponsored, as applicable, but is NOT a solicitation or recommendation to buy, sell or hold the stocks of the company(s) or engage in any investment activity under discussion. Kalkine Media is neither licensed nor qualified to provide investment advice through this platform. Users should make their own enquiries about any investments and Kalkine Media strongly suggests the users to seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice), as necessary.
The content published on Kalkine Media also includes feeds sourced from third-party providers. Kalkine does not assert any ownership rights over the content provided by these third-party sources. The inclusion of such feeds on the Website is for informational purposes only. Kalkine does not guarantee the accuracy, completeness, or reliability of the content obtained from third-party feeds. Furthermore, Kalkine Media shall not be held liable for any errors, omissions, or inaccuracies in the content obtained from third-party feeds, nor for any damages or losses arising from the use of such content.
Kalkine Media hereby disclaims any and all the liabilities to any user for any direct, indirect, implied, punitive, special, incidental or other consequential damages arising from any use of the Content on this website, which is provided without warranties. The views expressed in the Content by the guests, if any, are their own and do not necessarily represent the views or opinions of Kalkine Media. Some of the images/music that may be used on this website are copyrighted to their respective owner(s). Kalkine Media does not claim ownership of any of the pictures displayed/music used on this website unless stated otherwise. The images/music that may be used on this website are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have made reasonable efforts to accredit the source wherever it was indicated as or found to be necessary.
This disclaimer is subject to change without notice. Users are advised to review this disclaimer periodically for any updates or modifications.